Autor según el artículo: Bermúdez-López M., Arroyo D., Betriu À., Masana L., Fernández E., Valdivielso J.
Departamento: Medicina i Cirurgia
Autor/es de la URV: Masana Marín, Luis
Palabras clave: Type-2 diabetes-mellitus Subclinical atheromatosis Risk-factors Peritoneal-dialysis Lipoproteins Lipid abnormalities High-density-lipoprotein Hemodialysis-patients Dyslipidemia Chronic-renal-failure Chronic kidney-disease Chronic kidney disease Cardiovascular-disease Cardiovascular disease Atherosclerosis dyslipidemia chronic kidney disease cardiovascular disease atherosclerosis
Resumen: Introduction: Chronic kidney disease (CKD) is a world-wide health concern associated with a significantly higher cardiovascular morbidity and mortality. One of the principal cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and progressive atheromatous disease that cannot be explained by the classical lipid parameters used in the daily clinical practice. Areas covered: The current review summarizes prevailing knowledge on the role of lipids in atheromathosis in CKD patients, including an overview of lipoprotein metabolism highlighting the CKD-induced alterations. Moreover, to obtain information beyond traditional lipid parameters, new state-of-the-art technologies such as lipoprotein subfraction profiling and lipidomics are also reviewed. Finally, we analyse the potential of new lipoprotein subclasses as therapeutic targets in CKD. Expert opinion: The CKD-induced lipid profile has specific features distinct from the general population. Besides quantitative alterations, renal patients have a plethora of qualitative lipid alterations that cannot be detected by routine determinations and are responsible for the excess of cardiovascular risk. New parameters, such as lipoprotein particle number and size, together with new biomarkers obtained by lipidomics will personalize the management of these patients. Therefore, nephrologists need to be aware of new insights into lipoprotein metabolism to improve cardiovascular risk assessment.
Áreas temáticas: Pharmacology & pharmacy Pharmacology Molecular medicine Medicina ii Medicina i Interdisciplinar Farmacia Ensino Drug discovery Clinical biochemistry Ciências biológicas iii Ciências biológicas ii Ciência de alimentos
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 14728222
Direcció de correo del autor: luis.masana@urv.cat
Identificador del autor: 0000-0002-0789-4954
Fecha de alta del registro: 2023-02-18
Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion
Enlace a la fuente original: https://www.tandfonline.com/doi/abs/10.1080/14728222.2017.1369961?journalCode=iett20
URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Expert Opinion On Therapeutic Targets. 21 (10): 967-976
Referencia de l'ítem segons les normes APA: Bermúdez-López M., Arroyo D., Betriu À., Masana L., Fernández E., Valdivielso J. (2017). New perspectives on CKD-induced dyslipidemia. Expert Opinion On Therapeutic Targets, 21(10), 967-976. DOI: 10.1080/14728222.2017.1369961
DOI del artículo: 10.1080/14728222.2017.1369961
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2017
Tipo de publicación: Journal Publications
Repositori URV